

circumstances, the Administrator may enter a default final order pursuant to [21 CFR] § 1316.67.” *Id.* § 1301.43(f)(1). Here, the Government has requested final agency action based on Registrant’s default pursuant to 21 CFR 1301.43(c), (f), 1301.46. RFAA, at 3; *see also* 21 CFR 1316.67.

### Findings of Fact

The Agency finds that, in light of Registrant’s default, the factual allegations in the OSC are admitted. According to the OSC, on May 22, 2023, the Colorado Medical Board issued a Non-Disciplinary Interim Cessation of Practice Agreement, in which Registrant agreed to not practice medicine in the State of Colorado. RFAAX 2, at 2; *see* RFAAX 3. According to Colorado online records, of which the Agency takes official notice, Registrant’s medical license is under an “Active—Restricted” status with a stipulation that Registrant “Cannot Practice.”<sup>2</sup> Colorado Division of Professions and Occupations License Search, <https://apps2.colorado.gov/dora/licensing/lookup/licenselookup.aspx> (last visited date of signature of this Order). Accordingly, the Agency finds that Registrant is not licensed to practice medicine in Colorado, the state in which he is registered with DEA.

### Discussion

Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under 21 U.S.C. 823 “upon a finding that the registrant . . . has had his State license or registration suspended . . . [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances.” With respect to a practitioner, DEA has also long held that the possession of authority to dispense controlled substances under the laws of the state in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining

<sup>2</sup> Under the Administrative Procedure Act, an agency “may take official notice of facts at any stage in a proceeding—even in the final decision.” United States Department of Justice, Attorney General’s Manual on the Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e), “[w]hen an agency decision rests on official notice of a material fact not appearing in the evidence in the record, a party is entitled, on timely request, to an opportunity to show the contrary.” Accordingly, Registrant may dispute the Agency’s finding by filing a properly supported motion for reconsideration of findings of fact within fifteen calendar days of the date of this Order. Any such motion and response shall be filed and served by email to the other party and to the DEA Office of the Administrator, Drug Enforcement Administration at [dea.addo.attorneys@dea.gov](mailto:dea.addo.attorneys@dea.gov).

a practitioner’s registration. *See, e.g., James L. Hooper, D.O.*, 76 FR 71371, 71372 (2011), *pet. for rev. denied*, 481 F. App’x 826 (4th Cir. 2012); *Frederick Marsh Blanton, D.O.*, 43 FR 27616, 27617 (1978).<sup>3</sup>

According to Colorado statute, “dispense” means “to deliver a controlled substance to an ultimate user, patient, or research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery.” Colo. Rev. Stat. section 18–18–102(9) (2024). Further, a “practitioner” means a “physician . . . or other person licensed, registered, or otherwise permitted, by this state, to distribute, dispense, conduct research with respect to, administer, or to use in teaching or chemical analysis, a controlled substance in the course of professional practice or research.” *Id.* section 18–18–102(29).

Here, the undisputed evidence in the record is that Registrant lacks authority to practice medicine in Colorado. As discussed above a physician must be a licensed practitioner permitted to dispense a controlled substance in Colorado. Thus, because Registrant lacks authority to practice medicine in Colorado and, therefore, is not authorized to handle controlled substances in Colorado, Registrant is not eligible to maintain a DEA registration. Accordingly, the Agency will order that Registrant’s DEA registration be revoked.

### Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate

<sup>3</sup> This rule derives from the text of two provisions of the Controlled Substances Act (CSA). First, Congress defined the term “practitioner” to mean “a physician . . . or other person licensed, registered, or otherwise permitted, by . . . the jurisdiction in which he practices . . . , to distribute, dispense, . . . [or] administer . . . a controlled substance in the course of professional practice.” 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner’s registration, Congress directed that “[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices.” 21 U.S.C. 823(g)(1). Because Congress has clearly mandated that a practitioner possess state authority in order to be deemed a practitioner under the CSA, DEA has held repeatedly that revocation of a practitioner’s registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the state in which he practices. *See, e.g., James L. Hooper*, 76 FR 71371–72; *Sheran Arden Yeates, D.O.*, 71 FR 39130, 39131 (2006); *Dominick A. Ricci, D.O.*, 58 FR 51104, 51105 (1993); *Bobby Watts, D.O.*, 53 FR 11919, 11920 (1988); *Frederick Marsh Blanton*, 43 FR 27617.

of Registration No. FM0055841 issued to Stephen Matthews, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(g)(1), I hereby deny any pending applications of Stephen Matthews, M.D., to renew or modify this registration, as well as any other pending application of Stephen Matthews, M.D., for additional registration in Colorado. This Order is effective September 9, 2024.

### Signing Authority

This document of the Drug Enforcement Administration was signed on August 2, 2024, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA **Federal Register** Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

**Heather Achbach**,

*Federal Register Liaison Officer, Drug Enforcement Administration.*

[FR Doc. 2024–17715 Filed 8–8–24; 8:45 am]

BILLING CODE 4410–09–P

## DEPARTMENT OF JUSTICE

### Notice of Reestablishment of the Charter of the Task Force on Research on Violence Against American Indian and Alaska Native Women

**AGENCY:** Office on Violence Against Women, United States Department of Justice.

**ACTION:** Notice of renewal of charter.

**SUMMARY:** The charter of the Task Force on Research on Violence Against American Indian and Alaska Native Women (hereinafter “the Task Force”) has been reestablished.

**FOR FURTHER INFORMATION CONTACT:** Sherriann C. Moore, Deputy Director, Tribal Affairs Division, Office on Violence Against Women, United States Department of Justice, 145 N Street NE, Suite 10W.121, Washington, DC 20530, (202) 307–6026.

**SUPPLEMENTARY INFORMATION:** Authority for the Task Force is found in section 904(a)(3) of the Violence Against Women Act of 2005 (VAWA 2005), Public Law 109–162 (codified at 34 U.S.C. 10452 note) as amended by Section 907(a) of the Violence Against

Women Reauthorization Act, Public Law 113–4. The Task Force operates under the provisions of the Federal Advisory Committee Act of 1972, as amended (codified at 5 U.S.C. chapter 10).

The Deputy Attorney General has determined that the reestablishment of the Task Force is necessary and in the public interest and will provide information that will assist the National Institute of Justice (NIJ) to develop and implement a program of research on violence against American Indian and Alaska Native women, including domestic violence, dating violence, sexual assault, stalking, murder and sex trafficking. The research will evaluate the effectiveness of the Federal, State, and Tribal response to violence against American Indian and Alaska Native women and will propose recommendations to improve these responses. Title IX of VAWA 2005 also required the Attorney General to establish a Task Force to assist NIJ with development of the research study and the implementation of the recommendations.

The Attorney General, acting through the Director of the Office on Violence Against Women, originally established the Task Force on March 31, 2008. The charter to reestablish the Task Force was filed with the Agency on June 18, 2024 and was filed with Congress on July 11, 2024. The charter was re-filed with Congress with a technical amendment on July 29, 2024. The Task Force is comprised of representatives from national Tribal domestic violence and sexual assault nonprofit organizations, Tribal governments, and national Tribal organizations. Task Force members, with the exception of travel and per diem for official travel, shall serve without compensation.

The Deputy Director, Tribal Affairs Division, Office on Violence Against Women, shall serve as the Designated Federal officer for the Task Force.

**Rosemarie Hidalgo,**

*Director, Office on Violence Against Women.*

[FR Doc. 2024–17725 Filed 8–8–24; 8:45 am]

**BILLING CODE 4410–FX–P**

---

## NATIONAL SCIENCE FOUNDATION

### Advisory Committee for Cyberinfrastructure; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92–463, as amended), the National Science Foundation (NSF) announces the following meeting:

*Name and Committee Code:* Advisory Committee for Cyberinfrastructure (#25150).

*Date and Time:* September 12, 2024–September 13, 2024 10 a.m.–3:30 p.m. (eastern).

*Place:* NSF, 2415 Eisenhower Avenue, Alexandria, VA 22314 (In-Person)

The final meeting agenda and instructions to register and attend the meeting will be posted on the ACCI website: <https://new.nsf.gov/cise/oac/advisory-committee>.

*Type of Meeting:* Open.

*Contact Persons:* Walton, Amy, National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314; Telephone: (703) 292–4538.

*Minutes:* May be obtained from Christine Christy, National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314; Telephone: 703–292–2221 and will be posted within 90-days after the meeting end date to the ACCI website: <https://new.nsf.gov/cise/oac/advisory-committee>.

*Purpose of Meeting:* To provide advice, recommendations and counsel on major goals and policies pertaining to engineering programs and activities.

*Agenda:* Updates on NSF wide OAC activities <https://new.nsf.gov/cise/oac/advisory-committee>.

Dated: August 6, 2024.

**Crystal Robinson,**

*Committee Management Officer.*

[FR Doc. 2024–17788 Filed 8–8–24; 8:45 am]

**BILLING CODE 7555–01–P**

---

## NATIONAL SCIENCE FOUNDATION

### Advisory Committee for Biological Sciences; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92–463, as amended), the National Science Foundation (NSF) announces the following meeting:

*Name and Committee Code:* Advisory Committee for Biological Sciences (#1110)

*Date and Time:*

September 17, 2024; 10 a.m.–5 p.m. eastern

September 18, 2024; 10 a.m.–4 p.m. eastern

*Place:* U.S. National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314.

The meeting will be hybrid, with some Advisory Committee members participating in person and others participating virtually. For members of NSF and the external community, livestreaming will be accessible through the following pages:

September 17: <https://youtube.com/live/p6tMy00TKeg?feature=share>

September 18: <https://youtube.com/live/qlk5h1vQCrc?feature=share>

Information, including how to listen to the planned breakout sessions, will be posted on the meeting event web page prior to the meeting at: <https://new.nsf.gov/events/fall-2024-advisory-committee-meeting-directorate>.

*Type of Meeting:* Open.

*Contact Persons:* Dr. Karen C. Cone, U.S. National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314; Telephone: (703) 292–4967; Email: [kccone@nsf.gov](mailto:kccone@nsf.gov).

*Purpose of Meeting:* The Advisory Committee for the Directorate for Biological Sciences (BIO) provides advice and recommendations concerning major program emphases, directions, and goals for the research-related activities of the divisions that make up BIO.

*Summary of Minutes:* Minutes will be available on the BIO Advisory Committee website at <https://www.nsf.gov/bio/advisory.jsp> or can be obtained from the contact person listed above.

*Agenda:* Agenda items will include: Directorate business update; overview of NSF/BIO programs in support of the priority research areas of: Bioeconomy, Resilient Planet, and Artificial Intelligence; AC Breakout Groups to discuss opportunities and challenges for BIO in advancing these priority areas, followed by a report out from the breakout groups; overview of NSF and BIO's support of workforce education and training in the priority research areas of: Bioeconomy, Resilient Planet, and Artificial Intelligence; AC Breakout Groups to discuss needs, opportunities, and gaps for workforce development in these priority areas, followed by a report out from the breakout groups; discussion with leaders from the NSF Office of the Director; and other directorate matters.

Dated: August 5, 2024.

**Crystal Robinson,**

*Committee Management Officer.*

[FR Doc. 2024–17668 Filed 8–8–24; 8:45 am]

**BILLING CODE 7555–01–P**

---

## NATIONAL SCIENCE FOUNDATION

### Sunshine Act Meetings

The National Science Board hereby gives notice of the scheduling of a teleconference of the National Science Board/National Science Foundation Commission on Merit Review (MRX) for the transaction of National Science Board business pursuant to the NSF Act